CA3043000A1 - Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma - Google Patents

Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma Download PDF

Info

Publication number
CA3043000A1
CA3043000A1 CA3043000A CA3043000A CA3043000A1 CA 3043000 A1 CA3043000 A1 CA 3043000A1 CA 3043000 A CA3043000 A CA 3043000A CA 3043000 A CA3043000 A CA 3043000A CA 3043000 A1 CA3043000 A1 CA 3043000A1
Authority
CA
Canada
Prior art keywords
compound
formula
tension glaucoma
normal tension
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043000A
Other languages
English (en)
French (fr)
Inventor
Jason Lamar VITTITOW
Megan Elizabeth CAVET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Bausch and Lomb Inc
Original Assignee
Nicox SA
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA, Bausch and Lomb Inc filed Critical Nicox SA
Publication of CA3043000A1 publication Critical patent/CA3043000A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3043000A 2016-11-08 2017-11-07 Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma Pending CA3043000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419153P 2016-11-08 2016-11-08
US62/419,153 2016-11-08
PCT/EP2017/078486 WO2018087092A1 (en) 2016-11-08 2017-11-07 Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma

Publications (1)

Publication Number Publication Date
CA3043000A1 true CA3043000A1 (en) 2018-05-17

Family

ID=60421748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043000A Pending CA3043000A1 (en) 2016-11-08 2017-11-07 Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma

Country Status (7)

Country Link
US (1) US11058691B2 (https=)
JP (1) JP7055802B2 (https=)
KR (1) KR20190104993A (https=)
BR (1) BR112019009330A2 (https=)
CA (1) CA3043000A1 (https=)
MX (1) MX2019005321A (https=)
WO (1) WO2018087092A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6750473B2 (ja) * 2016-11-22 2020-09-02 沖電気工業株式会社 自動取引装置及び自動取引システム
EP4404936A1 (en) 2021-09-20 2024-07-31 Nicox SA Nitric oxide releasing prostamide as neuroprotective agent
CA3195291A1 (en) * 2022-04-13 2023-10-13 Caravel Therapeutics, Inc. Preservative-free ophthalmic pharmaceutical emulsion and its application
WO2024121867A1 (en) * 2022-12-09 2024-06-13 Sentiss Pharma Private Limited Pharmaceutical composition for glaucoma and ocular hypertension

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952581A (en) 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
WO1994008585A1 (en) 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
MXPA06007678A (es) 2004-01-05 2006-09-01 Nicox Sa Nitroxiderivados de prostaglandinas.
JP2009501150A (ja) 2005-06-29 2009-01-15 ファイザー・インク プロスタグランジン誘導体
EP1917239A1 (en) 2005-06-29 2008-05-07 Pfizer, Inc. Fluoroprostaglandins nitroderivatives
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas

Also Published As

Publication number Publication date
US11058691B2 (en) 2021-07-13
JP2019534296A (ja) 2019-11-28
KR20190104993A (ko) 2019-09-11
MX2019005321A (es) 2019-10-14
JP7055802B2 (ja) 2022-04-18
WO2018087092A1 (en) 2018-05-17
US20200179401A1 (en) 2020-06-11
BR112019009330A2 (pt) 2019-07-30

Similar Documents

Publication Publication Date Title
KR100850133B1 (ko) 프로스타글란딘 나이트로옥시 유도체
US11058691B2 (en) Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma
NL1032046C2 (nl) Prostaglandinederivaten.
JP2009500315A (ja) フルオロプロスタグランジンのニトロ誘導体
HK1096084B (en) Prostaglandin nitrooxyderivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241016

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241128

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251103